证券代码：603309 证券简称：维力医疗 公告编号：2025-015 广州维力医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 适用范围：供全麻或心肺人工复苏建立短期人工气道用 批准日期：2025年04月11日 有效期至：2030年04月10日 二、同类产品相关情况 根据国家药品监督管理局官网数据查询了解到的信息，截至目前，国内同行业 暂无其他厂家取得同类产品的医疗器械注册证书。 产品名称：一次性三通道可弯曲喉罩 注册证编号：粤械注准 20252080486 注册人名称：广州维力医疗器械股份有限公司 注册人住所：广州市番禺区化龙镇金湖工业城 C 区 4 号 生产地址：广州市番禺区化龙镇金湖工业城 C 区 4 号；广州市番禺区化龙镇国 贸大道南 45 号、47 号 结构及组成：由罩背、罩囊、通气管、接头 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-014 广州维力医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到广东省药品 监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 适用范围：供医疗部门在胸科手术麻醉时作分隔支气管通气一次性使用。 批准日期：2025 年 04 月 08 日 有效期至：2030 年 04 月 07 日 二、同类产品相关情况 产品名称：一次性使用可视双腔支气管插管 注册证编号：粤械注准 20252080498 注册人名称：广州维力医疗器械股份有限公司 注册人住所：广州市番禺区化龙镇金湖工业城 C 区 4 号 生产地址：广州市番禺区化龙镇金湖工业城 C 区 4 号；广州市番禺区化龙镇国 贸大道南 45 号、47 号 结构及组成：由插管（管身、左/右支气管套囊、气管套囊、充气管、指示球囊、 单向阀、四通接头、四通接头盖板、连接管 ...

最新一期业绩显示，2024年三季报，公司实现营业收入10.60亿元，同比8.53%；净利润1.67亿元，同比 15.85%，销售毛利率44.80%。 4月8日，维力医疗今日收盘10.49元，下跌4.90%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到14.27倍，总市值30.72亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)31维力医疗14.2715.961.6730.72亿行业平均 44.5846.844.6999.90亿行业中值28.5527.892.1941.61亿1硕世生物-1692.50-1692.501.0634.97亿2诺唯 赞-515.13-515.132.2287.58亿3博晖创新-345.95-213.003.8153.10亿4康泰医学-258.4530.322.6450.27亿5华 大基因-188.97206.701.95192.03亿6奥精医疗-104.74-104.741.3318.98亿7睿昂基因-72.49-72.491.1310.48亿 8华大智造-52.56-52.563.94314.89亿9热景生物-48.54-48.542.6787.00亿 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)31维力医疗16.9118.911.9836.40亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11328.30亿10中红医疗-54.40-37.010.8648.44 亿11天智航-46.58-46.584.8657.34亿 来源：金融界 4月1日，维力医疗今日收盘12.43元，上涨3.58%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到16.91倍，创62天以来新低，总市值36.40亿元。 ...

广州维力医疗器械股份有限公司 关于公司产品获得美国 FDA 批准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到美国食品药 品监督管理局（以下简称"FDA"）的通知，公司产品 Wellead® Hydrophilic Intermittent Catheter Ready to Use（维力浸水式间歇性导尿管）、Wellead® Hydrophilic Intermittent Catheter Compact（维力预润滑间歇性导尿管）获得了 美国 FDA 批准注册。现将有关情况公告如下： 一、医疗器械注册证的具体情况 证书编号：K241734 产品名称：Wellead® Hydrophilic Intermittent Catheter Ready to Use （维 力浸水式间歇性导尿管）、Wellead® Hydrophilic Intermittent Catheter Compact （维力预润滑间歇性导尿管） 产品分类：Ⅱ类 证券代码：60330 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-012 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）控股子公司苏州麦德 迅医疗科技有限公司（以下简称"苏州麦德迅"）于近日收到由江苏省科学技术 厅、江苏省财政厅、国家税务总局江苏省税务局联合颁发的《高新技术企业证书》， 具体情况如下： 证书编号：GR202432006743 发证日期：2024 年 11 月 19 日 有效期：三年 苏州麦德迅于 2021 年被认定为高新技术企业，本次高新技术企业认定是原 证书有效期满后进行的重新认定。 广州维力医疗器械股份有限公司 根据《中华人民共和国企业所得税法》等有关规定，苏州麦德迅自获得高新 技术企业认定当年起三年内（即 2024 年、2025 年、2026 年），将继续享受国家 关于高新技术企业的相关优惠政策，即按 15%的税率计缴企业所得税。 关于控股子公司通过高新技术企业重新认定的公告 特此公告。 广州维力医疗器械股份有限公司 董事会 2025 年 2 月 28 日 ...

Investment Rating - The investment rating for the company is "Buy" [1] Core Viewpoints - The medical catheter industry has significant development potential and market prospects, driven by an aging population and the advantages of domestic companies expanding overseas [5][6] - The global medical catheter market is projected to grow from approximately 188 billion yuan in 2023 to 278.3 billion yuan by 2030, with China's market size reaching 943.47 billion yuan in 2022 [5] - The company has a competitive advantage in product pricing and response speed, with expectations for increased market share as product layouts improve and overseas production capacity comes online [5][6] Company Overview - The company has been deeply engaged in the medical catheter field for twenty years, with a wide range of applications including urinary, anesthesia, urology, nursing, respiratory, and hemodialysis [6][20] - Revenue grew from 994 million yuan in 2019 to 1.388 billion yuan in 2023, with a compound annual growth rate (CAGR) of 8.71%, while net profit increased from 121 million yuan to 192 million yuan during the same period, with a CAGR of 12.27% [6][29] - The company has implemented a product line development strategy in the domestic market and is focusing on cultivating new growth points in the international market [6][8] Financial Forecast and Valuation - Revenue is expected to reach 1.542 billion yuan in 2024, 1.819 billion yuan in 2025, and 2.118 billion yuan in 2026, with year-on-year growth rates of 11.1%, 17.9%, and 16.4% respectively [9][11] - Net profit is projected to be 221 million yuan in 2024, 270 million yuan in 2025, and 323 million yuan in 2026, with year-on-year growth rates of 14.7%, 22.2%, and 19.8% respectively [9][11] - The company's gross margin is expected to remain stable, with projections of 43.8%, 43.9%, and 44.4% for 2024, 2025, and 2026 respectively [9][11] Industry Insights - The medical catheter industry is a fundamental and critical part of the medical device sector, widely used in medical diagnosis, treatment, and monitoring [6][46] - The low-value medical consumables market in China is expected to grow from 448 billion yuan in 2016 to 1.47 trillion yuan by 2024, with a compound annual growth rate of 16.01% [47][49] - The industry is characterized by a high concentration of international competitors, with domestic companies like Weili Medical having significant growth potential due to their smaller market share [5][6]

证券代码：603309 证券简称：维力医疗 公告编号：2025-011 广州维力医疗器械股份有限公司 关于控股股东股份延期质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 截至 2025 年 2 月 24 日，公司控股股东高博投资（香港）有限公司合计 持有公司股份 9,201.92 万股，占公司总股本的 31.42%，累计质押公司股份 3,000 万股，占其所持公司股份的 32.60%，占公司总股本的 10.24%。 广州维力医疗器械股份有限公司（以下简称"公司"）于 2025 年 2 月 24 日 接到公司控股股东高博投资（香港）有限公司（以下简称"高博投资"）函告， 获悉其将持有的本公司部分股份进行了延期质押，具体情况如下: 2019 年 2 月 26 日，高博投资将持有的公司 2,000 万股无限售流通股质押给 袁振，质押期限自 2019 年 2 月 26 日起至 2021 年 2 月 25 日。详见公司 2019 年 2 月 28 日披露于《中国证券报》《上海证券报》《证券时报》及上海证券交易 ...

Summary of Weili Medical Conference Call Company Overview - Weili Medical is expected to achieve a sales revenue growth rate of nearly 20% in 2024, with profits also increasing around 20% [3][4] - The company anticipates maintaining a growth rate of 20% to 25% annually from 2022 to 2024 [3] Growth Expectations - For 2025, Weili Medical projects a 20% growth in exports and a 15% growth in domestic sales, with overall sales revenue growth expected between 15% and 20% [3][4] - Profit growth is expected to exceed sales growth by approximately 5 percentage points [3] Market Focus - The company is focusing on overseas markets, particularly the United States, Europe, and South America, with expected growth rates of 25%-30% in the U.S. and Europe [3] - Domestic market growth is projected at around 15%, primarily driven by existing products [3] Product Development and Margins - Weili Medical aims to enhance its manufacturing capabilities for low-value medical consumables while developing high-value catheter products and surgical instruments to improve gross margins [3] - The gross margin for high-end products exported is approximately 70% [3][19] Capital Expenditure and Production Capacity - The company plans to invest approximately 100 million RMB in capital expenditures in 2025, mainly for the construction of factories in Mexico and Zhaoqing [15][13] - The construction of the Mexico factory is currently in the design phase, with production expected to start in 2026 [5][12] Product Line Growth - The company is focusing on the anesthesia and urology sectors, with a global market share of 20% in catheters [14] - New product launches are expected to contribute significantly to revenue growth, with some products projected to achieve growth rates between 30% and 80% [18] R&D and Automation - Weili Medical plans to increase its R&D spending in 2025, with a focus on automation to reduce costs [11][31] - The company is also enhancing its production capabilities through automation and advanced manufacturing techniques [11] Regional Performance - The South American market has shown rapid growth, with expectations for continued strong performance due to local operations and sales teams [24] - The Asia-Pacific region is expected to recover, with growth rates projected at 20% [32] Challenges and Risks - The company faces potential challenges from tariff policies affecting the Mexico factory, which could impact production costs and pricing competitiveness [5][25] - The introduction of new products in the domestic market has been slow due to anti-corruption measures, which are expected to improve gradually [21] Future Outlook - Weili Medical is positioned for steady growth, with a focus on high-margin products and expanding its presence in international markets [37] - The integration of AI technology is expected to enhance operational efficiency and support product development [36]

证书编号：GR202446000105 发证日期：2024 年 10 月 29 日 有效期：三年 海南维力于 2021 年被认定为高新技术企业，本次高新技术企业认定是原证 书有效期满后进行的重新认定。 证券代码：603309 证券简称：维力医疗 公告编号：2025-010 广州维力医疗器械股份有限公司 关于全资子公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州维力医疗器械股份有限公司（以下简称"公司"）全资子公司海南维力 医疗科技开发有限公司（以下简称"海南维力"）于近日收到由海南省科学技术 厅、海南省财政厅、国家税务总局海南省税务局、海南省工业和信息化厅联合颁 发的《高新技术企业证书》，具体情况如下： 根据《中华人民共和国企业所得税法》等有关规定，海南维力自获得高新技 术企业认定当年起三年内（即 2024 年、2025 年、2026 年），将继续享受国家关 于高新技术企业的相关优惠政策，即按 15%的税率计缴企业所得税。 特此公告。 广州维力医疗器械股份有限公司 董事会 2025 年 ...